Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

44.36 0.18 −0.40%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a

Alkermes plc (ALKS) Operating margin

Alert me on Operating margin

Alkermes plc's operating margin over the twelve months to 30 September 2026 was 3.66%, down 13.6 percentage points from fiscal 2025 (17.2%). Over the past ten years it has ranged from −35.7% (fiscal 2015) to 27.0% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2025 17.2% (9.79)
FY2024 27.0% 2.10
FY2023 24.9% 25.45
FY2022 −0.55% (8.88)
FY2021 8.33% 19.15
FY2020 −10.8% 4.17
FY2019 −15.0% (5.93)
FY2018 −9.06% 7.31
FY2017 −16.4% 11.61
FY2016 −28.0% 7.72

Quarterly newest first

Period Operating margin Change (points)
Sep 2026 7.50% 3.80
Jun 2026 3.70% 15.99
Mar 2026 −12.3% (27.40)
Dec 2025 15.1% (7.49)
43 more quarters

Against its own ten years

Low −35.7% High 27.0%
Ten-year median −9.06%
Current reading's percentile 63

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on ALKS